Spatially Fractionated Radiotherapy (SFRT)

OTHER2 trials

Sponsors

Second Affiliated Hospital of Nanchang University, Sichuan Cancer Hospital and Research Institute

Conditions

Non-Small Cell Lung Cancer

Phase 2

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

RecruitingNCT07131319

Second Affiliated Hospital of Nanchang UniversityNon-Small Cell Lung Cancer

Start: 2025-04-21End: 2028-12-31Target: 30Updated: 2026-06-25

Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial

Not yet recruitingNCT07775040

Sichuan Cancer Hospital and Research InstituteNon-Small Cell Lung Cancer

Start: 2026-08-20End: 2030-06-30Target: 43Updated: 2026-08-20